XML 68 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Other Balance Sheet Details (Tables)
3 Months Ended
Mar. 31, 2025
Other Balance Sheet Details [Abstract]  
Schedule of Inventories
Inventory consisted of the following:
(in millions)March 31,
2025
December 31,
2024
Raw materials$31.9 $33.7 
Work in process13.8 10.9 
Finished goods13.6 12.8 
59.3 57.4 
Less inventory reserves
(0.2)— 
Total inventory
$59.1 $57.4 
Schedule of Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consisted of the following:
(in millions)March 31,
2025
December 31,
2024
Sales rebates and reserves$154.6 $144.2 
Accrued development costs (including unpaid development milestones)
89.7 50.8 
Accrued employee related costs57.5 107.5 
Current branded prescription drug fee38.0 49.2 
Current income taxes payable
25.4 10.0 
Accounts payable and other accrued liabilities110.0 99.9 
Total accounts payable and accrued liabilities$475.2 $461.6 
Schedule of Other Noncurrent Liabilities
Other noncurrent liabilities consisted of the following:
(in millions)March 31,
2025
December 31,
2024
Noncurrent income taxes payable
$166.0 $160.7 
Other noncurrent liabilities
15.6 5.5 
Total other noncurrent liabilities$181.6 $166.2 
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.
(in millions)March 31,
2025
March 31,
2024
Cash and cash equivalents$194.1 $396.3 
Restricted cash included in other noncurrent assets
8.0 8.0 
Total cash, cash equivalents, and restricted cash$202.1 $404.3